Indian Council of Medical Research Signs MoAs for Clinical Trials
In a significant move to enhance India’s clinical research capabilities, the Indian Council of Medical Research (ICMR) has signed Memorandums of Agreement (MoAs) with key industry players to conduct First-in-Human Phase-1 Clinical Trials for four promising therapeutic candidates under its Phase 1 Clinical Trial Network.
As part of these strategic collaborations, ICMR will work with Aurigene Oncology Limited on a small molecule for multiple myeloma, partner with Indian Immunologicals Limited for Zika vaccine development, coordinate a seasonal influenza vaccine trial with Mynvax Private Limited, and explore CAR-T cell therapy advancements for chronic lymphocytic leukemia with ImmunoACT.
Union Health Minister J P Nadda praised the partnerships, calling them a pivotal step toward "affordable and accessible cutting-edge treatments" that solidify India’s standing as a global healthcare innovation leader.
The clinical trials will take place at four premier institutions: KEMH & GSMC in Mumbai, ACTREC in Navi Mumbai, SRM MCH&RC in Kattankulathur, and PGIMER in Chandigarh. A Central Coordinating Unit at ICMR Headquarters, New Delhi, will oversee the operations, ensuring the trials’ smooth execution through dedicated infrastructure and manpower at each site.
Published on Sep 14, 2024 at 02:31 PM IST
Join the Community of 2M+ Industry Professionals
Subscribe to our newsletter to get the latest insights and analysis.
Reference : https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/icmr-partners-with-industry-leaders-for-groundbreaking-first-in-human-phase-1-clinical-trials/113346100
